Base Genomics logo — Unlocking epigenetics, transforming patient outcomes

Base Genomics

Unlocking epigenetics, transforming patient outcomes

Founded 2019 United Kingdom Oxford, United Kingdom 11-50 employees Seed Total: $9.00M Biotechnology, Life Sciences

General Information

Company Name Base Genomics
Founded Year 2019
Location United Kingdom Oxford, United Kingdom
Employees 11-50
Industries Biotechnology, Life Sciences
Funding Stage Seed

BounceWatch is an independent company data service, not affiliated with Base Genomics. To contact Base Genomics, visit basegenomics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Base Genomics

Base Genomics is a UK-based biotechnology startup founded in 2019 with the slogan "Unlocking epigenetics, transforming patient outcomes". The company is focused on revolutionizing personalized medicine through the development of TAPS, a cutting-edge technology originating from the University of Oxford. This innovative technology aims to enhance the sensitivity, accuracy, and affordability of epigenetic analysis of DNA methylation, ultimately enabling early and precise detection of cancer. Base Genomics anticipates that TAPS will play a central role in various new healthcare and research applications. The company recently secured a significant £9.00M Seed Round investment on 03 June 2020 from Oxford Science Enterprises, demonstrating strong support and confidence from notable investors. Notably, Base Genomics is actively recruiting talent across multiple disciplines, including chemists, enzymologists, protein engineers, NGS specialists, bioinformaticians, and software developers as it continues to expand its team and scale its operations. The company's focus on leveraging cutting-edge technology and its commitment to addressing critical healthcare challenges position it as a compelling player in the biotechnology and life sciences industries. Interested individuals can explore available roles at basegenomics.com/join-us.

Taxonomy: cancer detection, epigenetic analysis, personalized medicine, TAPS technology, DNA methylation, early-stage cancer, minimal residual disease, University of Oxford, start-up

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round £9.00M 1
Oxford Science Enterprises
03 Jun 2020

Base Genomics Alternatives & Competitors

View All Alternatives
Base Genomics vs
Predicine
Predicine United States

Advancing precision medicine through next-generation liquid biopsy oncology platform

89 employees
Biotechnology, Health Care
Base Genomics vs

Cancer: a word, not a sentence!

Series D
32 employees
Biotechnology, Health Care
Base Genomics vs

LIQUID BIOPSY using disposable microfluidics to detect, take image, sort of Circulating Tumor Cells...

Seed
4 employees
Biotechnology, Life Sciences

FAQ About Base Genomics

Unlocking epigenetics, transforming patient outcomes
Base Genomics was founded in 2019.
Base Genomics is headquartered in Oxford, United Kingdom.
Base Genomics operates in Biotechnology and Life Sciences. Its work centres on cancer detection, epigenetic analysis, personalized medicine and TAPS technology.
Base Genomics has approximately 11-50 employees.
Base Genomics has completed 1 funding round, raising a total of $9.00M. The latest funding stage is Seed.
Top alternatives and competitors to Base Genomics include Predicine, Geneseeq Technology Inc., LIGHTHOUSE BIOTECH SRL, biomodal, ARNA Genomics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Base Genomics and Predicine are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Base Genomics, https://bouncewatch.com/company/base-genomics, updated 10 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes